Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNC 210

Next Previous
Drug Profile

BNC 210

Alternative Names: BNC-210; IW 2143

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionomics
  • Developer Bionomics; EmpathBio
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anxiety disorders
  • Phase II Agitation; Post-traumatic stress disorders
  • No development reported Depressive disorders

Most Recent Events

  • 20 May 2025 Neuphoria Therapeutics completes an end of phase II meeting with the US FDA for a phase IIb (SYMPHONY) trials in Post traumatic stress disorders
  • 20 May 2025 Neuphoria Therapeutics plans to initiate a phase IIb SYMPHONY trial in Post-traumatic stress disorder (PO) in the fourth quarter of 2025
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders(Combination therapy) in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top